Recent advances in the development of therapeutic peptides

Fetse, John; Kandel, Sashi; Mamani, Umar‐Farouk; Cheng, Kun

doi:10.1016/j.tips.2023.04.003

Cited by 24 publications

(7 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out of the 29 peptides reviewed in this article, only 1 can be administered orally, accounting for a mere 3.4% of the total approvals. Various tactics are considered to enhance the stability of peptides, but no novel approaches are in place [171,175].…”

Section: Discussionmentioning

confidence: 99%

Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989

Al Musaimi

2024

Cancers

View full text Add to dashboard Cite

The United States Food and Drug Administration (FDA) has approved a plethora of peptide-based drugs as effective drugs in cancer therapy. Peptides possess high specificity, permeability, target engagement, and a tolerable safety profile. They exhibit selective binding with cell surface receptors and proteins, functioning as agonists or antagonists. They also serve as imaging agents for diagnostic applications or can serve a dual-purpose as both diagnostic and therapeutic (theragnostic) agents. Therefore, they have been exploited in various forms, including linkers, peptide conjugates, and payloads. In this review, the FDA-approved prostate-specific membrane antigen (PSMA) peptide antagonists, peptide receptor radionuclide therapy (PRRT), somatostatin analogs, antibody–drug conjugates (ADCs), gonadotropin-releasing hormone (GnRH) analogs, and other peptide-based anticancer drugs are analyzed in terms of their chemical structures and properties, therapeutic targets and mechanisms of action, development journey, administration routes, and side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989

Al Musaimi

2024

Cancers

View full text Add to dashboard Cite

show abstract

“…About 155 peptides are in clinical trials, and over 500 are in preclinical development. In addition, four peptides reached global sales of over $1 billion as early as 2010, including glatiramer acetate ($4.0 billion), leuprolide acetate ($3.0 billion), octreotide acetate ($1.3 billion), and goserelin acetate ($1.1 billion) [58][59][60][61].…”

Section: Therapeutic Application Of Peptidesmentioning

confidence: 99%

An Update on Protein Kinases as Therapeutic Targets—Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein–Protein Interactions

Zerihun,

Rubin,

Silnitsky

et al. 2023

IJMS

View full text Add to dashboard Cite

Human protein kinases are highly-sought-after drug targets, historically harnessed for treating cancer, cardiovascular disease, and an increasing number of autoimmune and inflammatory conditions. Most current treatments involve small molecule protein kinase inhibitors that interact orthosterically with the protein kinase ATP-binding pocket. As a result, these compounds are often poorly selective and highly toxic. Part I of this series reviews the role of PKC isoforms in various human diseases, featuring cancer and cardiovascular disease, as well as translational examples of PKC modulation applied to human health and disease. In the present Part II, we discuss alternative allosteric binding mechanisms for targeting PKC, as well as novel drug platforms, such as modified peptides. A major goal is to design protein kinase modulators with enhanced selectivity and improved pharmacological properties. To this end, we use molecular docking analysis to predict the mechanisms of action for inhibitor–kinase interactions that can facilitate the development of next-generation PKC modulators.

show abstract

“…Peptides face challenges related to low stability and susceptibility to degradation by enzymatic peptidases, leading to a relatively short half-life in vivo [ 7 , 8 ]. Consequently, multiple strategies have been explored to improve the stability of peptides and facilitate their entry into the market [ 1 , 9 ]. Cyclisation is a prevalent chemical modification employed to restrict the structure of peptides, enhancing their interaction with targets and cellular permeability.…”

Section: Introductionmentioning

confidence: 99%

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms

Al Musaimi

2024

Biomolecules

View full text Add to dashboard Cite

Peptides continue to gain significance in the pharmaceutical arena. Since the unveiling of insulin in 1921, the Food and Drug Administration (FDA) has authorised around 100 peptides for various applications. Peptides, although initially derived from endogenous sources, have evolved beyond their natural origins, exhibiting favourable therapeutic effectiveness. Medicinal chemistry has played a pivotal role in synthesising valuable natural peptide analogues, providing synthetic alternatives with therapeutic potential. Furthermore, key chemical modifications have enhanced the stability of peptides and strengthened their interactions with therapeutic targets. For instance, selective modifications have extended their half-life and lessened the frequency of their administration while maintaining the desired therapeutic action. In this review, I analyse the FDA approval of natural peptides, as well as engineered peptides for diabetes treatment, growth-hormone-releasing hormone (GHRH), cholecystokinin (CCK), adrenocorticotropic hormone (ACTH), and α-melanocyte stimulating hormone (α-MSH) peptide analogues. Attention will be paid to the structure, mode of action, developmental journey, FDA authorisation, and the adverse effects of these peptides.

show abstract

Recent advances in the development of therapeutic peptides

Cited by 24 publications

References 85 publications

Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989

Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989

An Update on Protein Kinases as Therapeutic Targets—Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein–Protein Interactions

Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms

Contact Info

Product

Resources

About